Kieffer TL - Search Results

1

Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity.

Flamm SL, Muir AJ, Fried MW, Reddy KR, Nelson DR, Bzowej NH, Sullivan JC, Bengtsson L, DeMasi R, Wright CI, Kieffer TL, George S, Adda N, Dusheiko GM. Flamm SL, et al. Among authors: kieffer tl. J Clin Gastroenterol. 2015 Apr;49(4):336-44. doi: 10.1097/MCG.0000000000000150. J Clin Gastroenterol. 2015. PMID: 24828357

2

Futility rules for telaprevir combination treatment for patients with hepatitis C virus infection.

Adda N, Bartels DJ, Gritz L, Kieffer TL, Tomaka F, Bengtsson L, Luo D, Jacobson IM, Kauffman RS, Picchio G. Adda N, et al. Among authors: kieffer tl. Clin Gastroenterol Hepatol. 2013 Feb;11(2):193-5. doi: 10.1016/j.cgh.2012.10.045. Epub 2012 Nov 14. Clin Gastroenterol Hepatol. 2013. PMID: 23159528

3

Patterns of viral load decline with telaprevir-based therapy in patients with genotype 1 chronic HCV infection.

Picchio G, De Meyer S, Dierynck I, Ghys A, Gritz L, Kieffer TL, Bartels DJ, Witek J, Bengtsson L, Luo D, Kauffman RS, Adda N, Sarrazin C. Picchio G, et al. Among authors: kieffer tl. J Clin Virol. 2014 Mar;59(3):148-55. doi: 10.1016/j.jcv.2013.12.011. Epub 2014 Jan 6. J Clin Virol. 2014. PMID: 24462470

4

Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis.

Haseltine EL, Penney MS, George S, Kieffer TL. Haseltine EL, et al. Among authors: kieffer tl. J Viral Hepat. 2015 Sep;22(9):701-7. doi: 10.1111/jvh.12382. Epub 2015 Jan 13. J Viral Hepat. 2015. PMID: 25582683

5

VX-222, a non-nucleoside NS5B polymerase inhibitor, in telaprevir-based regimens for genotype 1 hepatitis C virus infection.

Di Bisceglie AM, Sulkowski M, Gane E, Jacobson IM, Nelson D, DeSouza C, Alves K, George S, Kieffer T, Zhang EZ, Kauffman R, Asmal M, Koziel MJ. Di Bisceglie AM, et al. Eur J Gastroenterol Hepatol. 2014 Jul;26(7):761-73. doi: 10.1097/MEG.0000000000000084. Eur J Gastroenterol Hepatol. 2014. PMID: 24901821 Clinical Trial.

6

Telaprevir for previously untreated chronic hepatitis C virus infection.

Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S; ADVANCE Study Team. Jacobson IM, et al. Among authors: kieffer tl. N Engl J Med. 2011 Jun 23;364(25):2405-16. doi: 10.1056/NEJMoa1012912. N Engl J Med. 2011. PMID: 21696307 Free article. Clinical Trial.

7

Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.

Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, Tigges A, Dierynck I, Spanks J, Dorrian J, Jiang M, Adiwijaya B, Ghys A, Beumont M, Kauffman RS, Adda N, Jacobson IM, Sherman KE, Zeuzem S, Kwong AD, Picchio G. Kieffer TL, et al. PLoS One. 2012;7(4):e34372. doi: 10.1371/journal.pone.0034372. Epub 2012 Apr 12. PLoS One. 2012. PMID: 22511937 Free PMC article.

8

Compensatory substitutions in the HCV NS3/4A protease cleavage sites are not observed in patients treated unsuccessfully with telaprevir combination treatment.

Sullivan JC, Zhang EZ, Bartels DJ, Tigges A, Dorrian JL, Kwong AD, Kieffer TL. Sullivan JC, et al. Among authors: kieffer tl. Virol J. 2012 Aug 6;9:147. doi: 10.1186/1743-422X-9-147. Virol J. 2012. PMID: 22866919 Free PMC article.

9

Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment.

Bartels DJ, Sullivan JC, Zhang EZ, Tigges AM, Dorrian JL, De Meyer S, Takemoto D, Dondero E, Kwong AD, Picchio G, Kieffer TL. Bartels DJ, et al. Among authors: kieffer tl. J Virol. 2013 Feb;87(3):1544-53. doi: 10.1128/JVI.02294-12. Epub 2012 Nov 14. J Virol. 2013. PMID: 23152524 Free PMC article.

10

Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials.

Sullivan JC, De Meyer S, Bartels DJ, Dierynck I, Zhang EZ, Spanks J, Tigges AM, Ghys A, Dorrian J, Adda N, Martin EC, Beumont M, Jacobson IM, Sherman KE, Zeuzem S, Picchio G, Kieffer TL. Sullivan JC, et al. Among authors: kieffer tl. Clin Infect Dis. 2013 Jul;57(2):221-9. doi: 10.1093/cid/cit226. Epub 2013 Apr 10. Clin Infect Dis. 2013. PMID: 23575197 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

51 results

Search Page